7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

The MaxCyte STX Scalable Transfection Presented at LabAutomation 2009

January 26, 2009

 

Gaithersburg, Maryland -– MaxCyte Inc., MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces the presentation of the MaxCyte® STX™ Scalable Transfection System at LabAutomation 2009 in the Rapid Fire Innovation Session in Palm Springs, CA. “The selection of the MaxCyte STX for this session attests to the uniqueness of MaxCyte’s large scale transfection technology. Using the MaxCyte STX, more than ten billion cells can be transfected in less than 30 minutes with one or more loading agents at efficiencies and cell viabilities often exceeding 90%. The speed, scale, and flexibility of our technology allow the development of an expanded range of relevant cell-based assays for drug discovery” says Dr. Karen Donato, Vice President of Sales and Marketing.

Tags:

Please reload

NEWS